AllAnalyst Report
Morningstar•March 23, 2021
Morningstar•March 23, 2021Bausch Health Companies Inc.: Bausch's Recovery on Track With B+L Spin on Horizon, Deleveraging Still Priority Number One
Summary
Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international (55% of revenue), Salix pharmaceuticals (25%), ortho dermatology (6%), and diversified products (14%), and approximately 13% of revenue is attributable to non-
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Biogen Inc.Apr 24, 2024 •
BIIB
- CTRA: Raising target price to $25.00Apr 24, 2024 •
CTRA
- CPRI: Lowering target price to $33.00Apr 24, 2024 •
CPRI
- COTY: Raising target price to $12.00Apr 24, 2024 •
COTY
- VIR: What does Argus have to say about VIR?Apr 24, 2024 •
VIR
Analyst Profile
Aaron Degagne
Equity AnalystAaron DeGagne is an equity analyst, financial services, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He contributes primarily to the research coverage of South American banks and Canadian insurance companies and conducts general research on the global financial-services sector.Before joining Morningstar in 2017, DeGagne was an accounting intern for Campgroup and completed two lending-group internships with RBC Capital Markets.DeGagne holds a Bachelor of Business Administration in finance from the University of Notre Dame’s Mendoza College of Business.